デフォルト表紙
市場調査レポート
商品コード
1006046

速効型インスリン市場の成長機会・成長予測 (2020-2027年):製品タイプ・適応症・流通経路・地域別

Rapid Acting Insulin Market by Product Type, Indication, and Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2020-2027

出版日: | 発行: Allied Market Research | ページ情報: 英文 168 Pages | 納期: 2~3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=128.03円
速効型インスリン市場の成長機会・成長予測 (2020-2027年):製品タイプ・適応症・流通経路・地域別
出版日: 2021年03月26日
発行: Allied Market Research
ページ情報: 英文 168 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の速効型インスリンの市場規模は予測期間中4.1%のCAGRで推移し、2019年の71億米ドルから、2027年には89億2500万米ドルの規模に成長すると予測されています。

世界的な糖尿病の有病率の上昇、ヒト遺伝子組み換えインスリンのR&Dに対する投資の拡大などの要因が同市場の成長を推進しています。一方で、低血糖などの副作用による速効性インスリンの採用への消極性が市場のさらなる成長を妨げる可能性があります。

当レポートでは、世界の速効型インスリンの市場を調査し、市場の定義と概要、新型コロナウイルス感染症 (COVID-19) およびその他の市場影響因子の分析、市場規模の推移・予測、製品タイプ・適応症・流通経路・地域/主要国など各種区分別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

  • 市場の定義と範囲
  • 主な調査結果
  • 主要企業の位置付け
  • ポーターのファイブフォース分析
  • 市場力学
    • 促進要因
    • 抑制要因
    • 市場機会
    • 影響分析
  • COVID-19:影響分析

第4章 市場分析・予測:製品タイプ別

  • リスプロ
  • アスパルト
  • グルリジン
    • 主要動向・成長要因・成長機会
    • 市場規模・予測:地域別
    • 市場分析:国別

第5章 市場分析・予測:適応症別

  • 1型糖尿病
  • 2型糖尿病
    • 市場規模・予測:地域別
    • 市場分析:国別

第6章 市場分析・予測:流通経路別

  • 病院薬局
  • ドラッグストア・小売薬局
  • オンラインプロバイダー
    • 市場規模・予測:地域別
    • 市場分析:国別

第7章 市場分析・予測:地域・主要国別

  • 北米
  • 欧州
  • アジア太平洋
  • ラテンアメリカ・中東・アフリカ
    • 主要動向・成長要因・成長機会
    • 市場分析:国別
    • 市場規模・予測:タイプ別
    • 市場規模・予測:適応症別
    • 市場規模・予測:流通経路別

第8章 企業プロファイル

  • ADOCIA SAS
  • Biocon Limited
  • Eli Lilly And Company
  • Gan & Lee Pharmaceuticals
  • Geropharm LLC
  • Mannkind Corporation
  • Novo Nordisk A/S
  • Sanofi S.A.
  • Wockhadt Ltd.
図表

LIST OF TABLES

  • TABLE 01.RAPID ACTING INSULIN MARKET, BY PRODUCT TYPE, 2019-2027 ($MILLION)
  • TABLE 02.RAPID ACTING INSULIN MARKET FOR LISPRO INSULIN, BY REGION, 2019-2027 ($MILLION)
  • TABLE 03.RAPID ACTING INSULIN MARKET FOR ASPART INSULIN, BY REGION, 2019-2027 ($MILLION)
  • TABLE 04.RAPID ACTING INSULIN MARKET FOR GLULISINE INSULIN, BY REGION, 2019-2027 ($MILLION)
  • TABLE 05.RAPID ACTING INSULIN MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 06.RAPID ACTING INSULIN MARKET FOR TYPE 1 DIABETES, BY REGION, 2019-2027 ($MILLION)
  • TABLE 07.RAPID ACTING INSULIN MARKET FOR TYPE 2 DIABETES, BY REGION, 2019-2027 ($MILLION)
  • TABLE 08.RAPID ACTING INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 09.RAPID ACTING INSULIN MARKET FOR HOSPITAL PHARMACY, BY REGION, 2019-2027 ($MILLION)
  • TABLE 10.RAPID ACTING INSULIN MARKET FOR DRUG STORE & RETAIL PHARMACY, BY REGION, 2019-2027 ($MILLION)
  • TABLE 11.RAPID ACTING INSULIN MARKET FOR ONLINE PROVIDERS, BY REGION, 2019-2027 ($MILLION)
  • TABLE 12.RAPID ACTING INSULIN MARKET, BY REGION, 2019-2027 ($MILLION)
  • TABLE 13.NORTH AMERICA RAPID ACTING INSULIN MARKET, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 14.U.S. RAPID ACTING INSULIN MARKET, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 15.U.S. RAPID ACTING INSULIN MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 16.U.S. RAPID ACTING INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 17.CANADA RAPID ACTING INSULIN MARKET, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 18.CANADA RAPID ACTING INSULIN MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 19.CANADA RAPID ACTING INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 20.MEXICO RAPID ACTING INSULIN MARKET, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 21.MEXICO RAPID ACTING INSULIN MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 22.MEXICO RAPID ACTING INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 23.NORTH AMERICA RAPID ACTING INSULIN MARKET, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 24.NORTH AMERICA RAPID ACTING INSULIN MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 25.NORTH AMERICA RAPID ACTING INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 26.EUROPE RAPID ACTING INSULIN MARKET, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 27.GERMANY RAPID ACTING INSULIN MARKET, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 28.GERMANY RAPID ACTING INSULIN MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 29.GERMANY RAPID ACTING INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 30.UK RAPID ACTING INSULIN MARKET, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 31.UK RAPID ACTING INSULIN MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 32.UK RAPID ACTING INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 33.FRANCE RAPID ACTING INSULIN MARKET, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 34.FRANCE RAPID ACTING INSULIN MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 35.FRANCE RAPID ACTING INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 36.ITALY RAPID ACTING INSULIN MARKET, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 37.ITALY RAPID ACTING INSULIN MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 38.ITALY RAPID ACTING INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 39.SPAIN RAPID ACTING INSULIN MARKET, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 40.SPAIN RAPID ACTING INSULIN MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 41.SPAIN RAPID ACTING INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 42.REST OF EUROPE RAPID ACTING INSULIN MARKET, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 43.REST OF EUROPE RAPID ACTING INSULIN MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 44.REST OF EUROPE RAPID ACTING INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 45.EUROPE RAPID ACTING INSULIN MARKET, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 46.EUROPE RAPID ACTING INSULIN MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 47.EUROPE RAPID ACTING INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 48.ASIA-PACIFIC RAPID ACTING INSULIN MARKET, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 49.CHINA RAPID ACTING INSULIN MARKET, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 50.CHINA RAPID ACTING INSULIN MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 51.CHINA RAPID ACTING INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 52.JAPAN RAPID ACTING INSULIN MARKET, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 53.JAPAN RAPID ACTING INSULIN MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 54.JAPAN RAPID ACTING INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 55.AUSTRALIA RAPID ACTING INSULIN MARKET, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 56.AUSTRALIA RAPID ACTING INSULIN MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 57.AUSTRALIA RAPID ACTING INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 58.INDIA RAPID ACTING INSULIN MARKET, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 59.INDIA RAPID ACTING INSULIN MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 60.INDIA RAPID ACTING INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 61.REST OF ASIA-PACIFIC RAPID ACTING INSULIN MARKET, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 62.REST OF ASIA-PACIFIC RAPID ACTING INSULIN MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 63.REST OF ASIA-PACIFIC RAPID ACTING INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 64.ASIA-PACIFIC RAPID ACTING INSULIN MARKET, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 65.ASIA-PACIFIC RAPID ACTING INSULIN MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 66.ASIA-PACIFIC RAPID ACTING INSULIN MARKET, BY DISTRIBUTION MARKET, 2019-2027 ($MILLION)
  • TABLE 67.LAMEA RAPID ACTING INSULIN MARKET, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 68.LATIN AMERICA RAPID ACTING INSULIN MARKET, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 69.LATIN AMERICA RAPID ACTING INSULIN MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 70.LATIN AMERICA RAPID ACTING INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 71.MIDDLE EAST & AFRICA RAPID ACTING INSULIN MARKET, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 72.MIDDLE EAST & AFRICARAPID ACTING INSULIN MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 73.MIDDLE EAST & AFRICARAPID ACTING INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 74.LAMEA RAPID ACTING INSULIN MARKET, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 75.LAMEA RAPID ACTING INSULIN MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 76.LAMEA RAPID ACTING INSULIN MARKET, BY END USER, 2019-2027 ($MILLION)
  • TABLE 01.ADOCIA: COMPANY SNAPSHOT
  • TABLE 02.ADOCIA: OPERATING SEGMENTS
  • TABLE 03.ADOCIA: PRODUCT PORTFOLIO
  • TABLE 04.BIOCON: COMPANY SNAPSHOT
  • TABLE 05.BIOCON: OPERATING SEGMENTS
  • TABLE 06.BIOCON: PRODUCT PORTFOLIO
  • TABLE 07.ELI LILLY: COMPANY SNAPSHOT
  • TABLE 08.ELI LILLY: OPERATING SEGMENTS
  • TABLE 09.ELI LILLY: PRODUCT PORTFOLIO
  • TABLE 10.GAN&LEE: COMPANY SNAPSHOT
  • TABLE 11.GAN&LEE: PRODUCT PORTFOLIO
  • TABLE 12.GEROPHARM: COMPANY SNAPSHOT
  • TABLE 13.GEROPHARM: OPERATING SEGMENTS
  • TABLE 14.GEROPHARM: PRODUCT PORTFOLIO
  • TABLE 15.MANNKIND: COMPANY SNAPSHOT
  • TABLE 16.MANNKIND: OPERATING SEGMENTS
  • TABLE 17.MANNKIND: PRODUCT PORTFOLIO
  • TABLE 18.NOVO NORDISK: COMPANY SNAPSHOT
  • TABLE 19.NOVO NORDISK: OPERATING SEGMENTS
  • TABLE 20.NOVO NORDISK: PRODUCT PORTFOLIO
  • TABLE 21.SANOFI: COMPANY SNAPSHOT
  • TABLE 22.SANOFI: PRODUCT PORTFOLIO
  • TABLE 23.WOCKHARDT: COMPANY SNAPSHOT
  • TABLE 24.WOCKHARDT: OPERATING SEGMENTS
  • TABLE 25.WOCKHARDT: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01.GLOBAL RAPID ACTING INSULIN MARKET SEGMENTATION
  • FIGURE 02.TOP INVESTMENT POCKETS
  • FIGURE 03.TOP WINNING STRATEGIES, 2018-2021
  • FIGURE 04.TOP WINNING STRATEGIES, BY YEAR, 2018-2021
  • FIGURE 05.TOP WINNING STRATEGIES: NATURE AND TYPE, 2018-2021
  • FIGURE 06.TOP PLAYER POSITIONING, 2019
  • FIGURE 07.MODERATE BARGANING POWER OF BUYERS
  • FIGURE 08.MODERATE BARGANING POWER OF SUPPLIERS
  • FIGURE 09.MODERATE THREAT OF SUBSTITUTION
  • FIGURE 10.MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 11.HIGH COMPETITIVE RIVALRY
  • FIGURE 12.IMPACT ANALYSIS
  • FIGURE 13.COMPARATIVE ANALYSIS OF RAPID ACTING INSULIN MARKET, FOR LISPRO INSULIN BY COUNTRY, 2019-2027 (%)
  • FIGURE 14.COMPARATIVE ANALYSIS OF RAPID ACTING INSULIN MARKET, FOR ASPART INSULIN BY COUNTRY, 2019-2027 (%)
  • FIGURE 15.COMPARATIVE ANALYSIS OF RAPID ACTING INSULIN MARKET, FOR GLULISINE INSULIN BY COUNTRY, 2019-2027 (%)
  • FIGURE 16.COMPARATIVE ANALYSIS OF RAPID ACTING INSULIN MARKET, FOR TYPE 1 DIABETES BY COUNTRY, 2019-2027 (%)
  • FIGURE 17.COMPARATIVE ANALYSIS OF RAPID ACTING INSULIN MARKET, FOR TYPE 2 DIABETES BY COUNTRY, 2019-2027 (%)
  • FIGURE 18.COMPARATIVE ANALYSIS OF RAPID ACTING INSULIN MARKET, FOR HOSPITAL PHARMACY BY COUNTRY, 2019-2027 (%)
  • FIGURE 19.COMPARATIVE ANALYSIS OF RAPID ACTING INSULIN MARKET, FOR DRUG STORE & RETAIL PHARMACY BY COUNTRY, 2019-2027 (%)
  • FIGURE 20.COMPARATIVE ANALYSIS OF RAPID ACTING INSULIN MARKET, FOR ONLINE PROVIDERS BY COUNTRY, 2019-2027 (%)
  • FIGURE 21.U.S. RAPID ACTING INSULIN MARKET, 2019-2027 ($MILLION)
  • FIGURE 22.CANADA RAPID ACTING INSULIN MARKET, 2019-2027 ($MILLION)
  • FIGURE 23.MEXICO RAPID ACTING INSULIN MARKET, 2019-2027 ($MILLION)
  • FIGURE 24.GERMANY RAPID ACTING INSULIN MARKET, 2019-2027 ($MILLION)
  • FIGURE 25.UK RAPID ACTING INSULIN MARKET, 2019-2027 ($MILLION)
  • FIGURE 26.FRANCE RAPID ACTING INSULIN MARKET, 2019-2027 ($MILLION)
  • FIGURE 27.ITALY RAPID ACTING INSULIN MARKET, 2019-2027 ($MILLION)
  • FIGURE 28.SPAIN RAPID ACTING INSULIN MARKET, 2019-2027 ($MILLION)
  • FIGURE 29.REST OF EUROPE RAPID ACTING INSULIN MARKET, 2019-2027 ($MILLION)
  • FIGURE 30.CHINA RAPID ACTING INSULIN MARKET, 2019-2027 ($MILLION)
  • FIGURE 31.JAPAN RAPID ACTING INSULIN MARKET, 2019-2027 ($MILLION)
  • FIGURE 32.AUSTRALIA RAPID ACTING INSULIN MARKET, 2019-2027 ($MILLION)
  • FIGURE 33.INDIA RAPID ACTING INSULIN MARKET, 2019-2027 ($MILLION)
  • FIGURE 34.REST OF ASIA-PACIFIC RAPID ACTING INSULIN MARKET, 2019-2027 ($MILLION)
  • FIGURE 35.LATIN AMERICA RAPID ACTING INSULIN MARKET, 2019-2027 ($MILLION)
  • FIGURE 36.MIDDLE EAST & AFRICA RAPID ACTING INSULIN MARKET, 2019-2027 ($MILLION)
  • FIGURE 01.ADOCIA: REVENUE, 2017-2019 ($MILLION)
  • FIGURE 02.BIOCON: REVENUE, 2018-2020 ($MILLION)
  • FIGURE 03.BIOCON: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 04.BIOCON: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 05.ELI LILLY: REVENUE, 2018-2019 ($MILLION)
  • FIGURE 06.ELI LILLY: REVENUE SHARE BY SEGMENT, 2019 (%)
  • FIGURE 07.ELI LILLY: REVENUE SHARE BY REGION, 2019 (%)
  • FIGURE 08.MANNKIND: REVENUE, 2019-2020 ($MILLION)
  • FIGURE 09.NOVO NORDISK: REVENUE, 2018-2020 ($MILLION)
  • FIGURE 10.NOVO NORDISK: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 11.NOVO NORDISK: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 12.SANOFI: REVENUE, 2017-2019 ($MILLION)
  • FIGURE 13.SANOFI: REVENUE SHARE BY SEGMENT, 2019 (%)
  • FIGURE 14.SANOFI: REVENUE SHARE BY REGION, 2019 (%)
  • FIGURE 15.WOCKHARDT: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 16.WOCKHARDT: REVENUE SHARE BY REGION, 2019 (%)
目次
Product Code: LI_2110964 / A10599

The global rapid acting insulin market was valued at $7,100 million in 2019, and is projected to reach $8,925 million by 2027 at a CAGR of 4.1% from 2020 to 2027.

Rapid acting insulin are insulin analogs that have the fastest onset of action than other analogues of insulin These types of insulin analogs enter into the bloodstream within few minutes; hence, it is necessary to inject it after before 5 to 10 minutes of food intake. In addition, rapid acting insulin act very quickly, they can lead to an increased chance of hypoglycemia. Some of the rapid acting insulin available in the market include Fiasp, Humalog, NovoRapid, Apidra and others.

The growth of the global rapid acting insulin market is majorly driven by the surge in prevalence of diabetes worldwide, increase in investment in research and development (R&D) for human recombinant insulin is expected to drive the need for insulin used in management of diabetes thereby boosting the growth of the market. Furthermore, sedentary & unhealthy lifestyles increase all causes of mortality, double the risk of diabetes, because of overweight or obesity, an unhealthy diet and physical inactivity, which account for about 80% of the increase in prevalence of diabetes. However, the reluctance in adoption of rapid acting insulin due to the side effect, such as hypoglycemia, may hinder the growth of the industry. Conversely, untapped market and undiagnosed population in developing regions are expected to provide lucrative growth opportunities for the market growth.

The global rapid acting insulin market is segmented on the basis of product type, indication, distribution channel, and region. By product type, the market is segregated into insulin lispro, insulin aspart and insulin glulisine. Depending on indication, it is fragmented into type 1 diabetes and type 2 diabetes. Furthermore, the market is divided on the basis of distribution channel into hospital pharmacies, drug stores & retail pharmacies, and online providers. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS

  • The study provides an in-depth analysis of the global rapid acting insulin market along with the current trends and future estimations to explain the imminent investment pockets.
  • The report provides a quantitative analysis for the period of 2019-2027 to enable stakeholders to capitalize on the prevailing market opportunities.
  • Extensive analysis of the market by components helps to understand various types of instruments used across regions.
  • Comprehensive analysis of all regions is provided to determine the prevailing opportunities in these regions.
  • Key market players have been profiled in the report and their strategies have been analyzed thoroughly to understand the competitive outlook of the global market.
  • Extensive analysis of the market is conducted by closely following key product positioning and monitoring the top contenders within the market framework.

KEY MARKET SEGMENTS

By Product Type

  • Insulin Lispro
  • Insulin Aspart
  • Insulin Glulisine

By Indication

  • Type 1 Diabetes
  • Type 2 Diabetes

By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Providers

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Australia
  • Japan
  • India
  • China
  • South Korea
  • Rest of Asia-Pacific
  • o
  • LAMEA
  • Latin America
  • Middle East & Africa
  • o

KEY MARKET PLAYERS

  • ADOCIA SAS
  • Biocon Limited
  • Eli Lilly and Company
  • Gan & Lee Pharmaceuticals
  • Geropharm LLC
  • Mannkind Corporation
  • Novo Nordisk A/S
  • Sanofi S.A.
  • Wockhadt Ltd.

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.1.Key benefits for stakeholders
  • 1.2.Key market segments
    • 1.2.1.List of key players profiled in the report
  • 1.3.Research methodology
    • 1.3.1.Secondary research
    • 1.3.2.Primary research
    • 1.3.3.Analyst tools and models
    • 1.3.4.Primary research

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
    • 3.2.2.Top winning strategies, 2019
  • 3.3.Top player positioning, 2019
  • 3.4.Porter's five forces analysis
  • 3.5.Market dynamics
    • 3.5.1.Drivers
      • 3.5.1.1.Sedentary and unhealthy lifestyle
      • 3.5.1.2.Increased availability of continuous glucose monitoring
      • 3.5.1.3.Increasing investment in research and development (R&D) for human recombinant insulin
      • 3.5.1.4.Increase in government expenditure on healthcare
    • 3.5.2.Restraints
      • 3.5.2.1.Adverse effects associated with the use of rapid acting insulin
    • 3.5.3.Opportunities
      • 3.5.3.1.Untapped opportunities and undiagnosed population in developing regions
    • 3.5.4.Impact analysis
  • 3.6.COVID-19 Impact Analysis On Rapid Acting Insulin Market

CHAPTER 4:RAPID ACTING INSULIN MARKET, BY PRODUCT TYPE

  • 4.1.Overview
    • 4.1.1.Market size and forecast
  • 4.2.Lispro Insulin
    • 4.2.1.Key market trends, growth factors, and opportunities
    • 4.2.2.Market size and forecast, by region
    • 4.2.3.Market analysis, by country
  • 4.3.Aspart Insulin
    • 4.3.1.Key market trends, growth factors, and opportunities
    • 4.3.2.Market size and forecast, by region
    • 4.3.3.Market analysis, by country
  • 4.4.Glulisine Insulin
    • 4.4.1.Key market trends, growth factors, and opportunities
    • 4.4.2.Market size and forecast, by region
    • 4.4.3.Market analysis, by country

CHAPTER 5:RAPID ACTING INSULIN MARKET, BY INDICATION

  • 5.1.Overview
    • 5.1.1.Market size and forecast
  • 5.2.Type 1 Diabetes
    • 5.2.1.Market size and forecast, by region
    • 5.2.2.Market analysis, by country
  • 5.3.Type 2 Diabetes
    • 5.3.1.Market size and forecast, by region
    • 5.3.2.Market analysis, by country

CHAPTER 6:RAPID ACTING INSULIN MARKET, BY DISTRIBUTION CHANNEL

  • 6.1.Overview
    • 6.1.1.Market size and forecast
  • 6.2.Hospital Pharmacies
    • 6.2.1.Market size and forecast, by region
    • 6.2.2.Market analysis, by country
  • 6.3.Drug Stores & retail pharmacies
    • 6.3.1.Market size and forecast, by region
    • 6.3.2.Market analysis, by country
  • 6.4.Online providers
    • 6.4.1.Market size and forecast, by region
    • 6.4.2.Market analysis, by country

CHAPTER 7:RAPID ACTING INSULIN MARKET, BY REGION

  • 7.1.Overview
    • 7.1.1.Market size and forecast
  • 7.2.North America
    • 7.2.1.Key market trends, growth factors, and opportunities
    • 7.2.2.North America rapid acting insulin market, by country
      • 7.2.2.1.U.S.
      • 7.2.2.1.1.Market size and forecast, by product
      • 7.2.2.1.2.Market size and forecast, by indication
      • 7.2.2.1.3.Market size and forecast, by distribution channel
      • 7.2.2.2.Canada
      • 7.2.2.2.1.Market size and forecast, by product
      • 7.2.2.2.2.Market size and forecast, by indication
      • 7.2.2.2.3.Market size and forecast, by distribution channel
      • 7.2.2.3.Mexico
      • 7.2.2.3.1.Market size and forecast, by type
      • 7.2.2.3.2.Market size and forecast, by indication
      • 7.2.2.3.3.Market size and forecast, by distribution channel
    • 7.2.3.North America market size and forecast, type
    • 7.2.4.North America market size and forecast, indication
    • 7.2.5.North America market size and forecast, by distribution channel
  • 7.3.Europe
    • 7.3.1.Key market trends, growth factors, and opportunities
    • 7.3.2.Europe rapid acting insulin market, by country
      • 7.3.2.1.Germany
      • 7.3.2.1.1.Market size and forecast, by type
      • 7.3.2.1.2.Market size and forecast, by indication
      • 7.3.2.1.3.Market size and forecast, by distribution channel
      • 7.3.2.2.UK
      • 7.3.2.2.1.Market size and forecast, by type
      • 7.3.2.2.2.Market size and forecast, by indication
      • 7.3.2.2.3.Market size and forecast, by distribution channel
      • 7.3.2.3.France
      • 7.3.2.3.1.Market size and forecast, by type
      • 7.3.2.3.2.Market size and forecast, by indication
      • 7.3.2.3.3.Market size and forecast, by distribution channel
      • 7.3.2.4.Italy
      • 7.3.2.4.1.Market size and forecast, by type
      • 7.3.2.4.2.Market size and forecast, by indication
      • 7.3.2.4.3.Market size and forecast, by distribution channel
      • 7.3.2.5.Spain
      • 7.3.2.5.1.Market size and forecast, by type
      • 7.3.2.5.2.Market size and forecast, by indication
      • 7.3.2.5.3.Market size and forecast, by distribution channel
      • 7.3.2.6.Rest of Europe
      • 7.3.2.6.1.Market size and forecast, by type
      • 7.3.2.6.2.Market size and forecast, by indication
      • 7.3.2.6.3.Market size and forecast, by distribution channel
    • 7.3.3.Europe market size and forecast, type
    • 7.3.4.Europe market size and forecast, indication
    • 7.3.5.Europe market size and forecast, by distribution channel
  • 7.4.Asia-Pacific
    • 7.4.1.Key market trends, growth factors, and opportunities
    • 7.4.2.Asia-Pacific Rapid acting insulin market, by country
      • 7.4.2.1.China
      • 7.4.2.1.1.Market size and forecast, by type
      • 7.4.2.1.2.Market size and forecast, by indication
      • 7.4.2.1.3.Market size and forecast, by distribution channel
      • 7.4.2.2.Japan
      • 7.4.2.2.1.Market size and forecast, by type
      • 7.4.2.2.2.Market size and forecast, by indication
      • 7.4.2.2.3.Market size and forecast, by distribution channel
      • 7.4.2.3.Australia
      • 7.4.2.3.1.Market size and forecast, by type
      • 7.4.2.3.2.Market size and forecast, by indication
      • 7.4.2.3.3.Market size and forecast, by distribution channel
      • 7.4.2.4.India
      • 7.4.2.4.1.Market size and forecast, by type
      • 7.4.2.4.2.Market size and forecast, by indication
      • 7.4.2.4.3.Market size and forecast, by distribution channel
      • 7.4.2.5.Rest of Asia-Pacific
      • 7.4.2.5.1.Market size and forecast, by type
      • 7.4.2.5.2.Market size and forecast, by indication
      • 7.4.2.5.3.Market size and forecast, by distribution channel
    • 7.4.3.Asia-Pacific market size and forecast, by type
    • 7.4.4.Asia-Pacific market size and forecast, by indication
    • 7.4.5.Asia-Pacific market size and forecast, by distribution channel
  • 7.5.LAMEA
    • 7.5.1.Key market trends, growth factors, and opportunities
    • 7.5.2.LAMEA rapid acting insulin market, by country
      • 7.5.2.1.Latin America
      • 7.5.2.1.1.Market size and forecast, by type
      • 7.5.2.1.2.Market size and forecast, by indication
      • 7.5.2.1.3.Market size and forecast, by distribution channel
      • 7.5.2.2.Middle East & Africa
      • 7.5.2.2.1.Market size and forecast, by type
      • 7.5.2.2.2.Market size and forecast, by indication
      • 7.5.2.2.3.Market size and forecast, by distribution channel
    • 7.5.3.LAMEA market size and forecast, by type
    • 7.5.4.LAMEA market size and forecast, by indication
    • 7.5.5.LAMEA market size and forecast, by distribution channel

CHAPTER 8:COMPANY PROFILES

  • 8.1.ADOCIA SAS
    • 8.1.1.Company overview
    • 8.1.2.Company snapshot
    • 8.1.3.Operating business segments
    • 8.1.4.Product portfolio
    • 8.1.5.Business performance
  • 8.2.Biocon Limited
    • 8.2.1.Company overview
    • 8.2.2.Company snapshot
    • 8.2.3.Operating business segment
    • 8.2.4.Product portfolio
    • 8.2.5.Business performance
    • 8.2.6.Key strategic moves and developments
  • 8.3.Eli Lilly And Company
    • 8.3.1.Company overview
    • 8.3.2.Company snapshot
    • 8.3.3.Operating business segment
    • 8.3.4.Product portfolio
    • 8.3.5.Business performance
    • 8.3.6.Key strategic moves and developments
  • 8.4.Gan & Lee Pharmaceuticals
    • 8.4.1.Company overview
    • 8.4.2.Company snapshot
    • 8.4.3.Operating business segments
    • 8.4.4.Product portfolio
    • 8.4.5.Key strategic moves and developments
  • 8.5.Geropharm LLC
    • 8.5.1.Company overview
    • 8.5.2.Company snapshot
    • 8.5.3.Operating business segments
    • 8.5.4.Product portfolio
    • 8.5.5.Key strategic moves and developments
  • 8.6.Mannkind Corporation
    • 8.6.1.Company overview
    • 8.6.2.Company snapshot
    • 8.6.3.Operating business segment
    • 8.6.4.Product portfolio
    • 8.6.5.Business performance
  • 8.7.Novo Nordisk A/S
    • 8.7.1.Company overview
    • 8.7.2.Company snapshot
    • 8.7.3.Operating business segment
    • 8.7.4.Product portfolio
    • 8.7.5.Business performance
    • 8.7.6.Key strategic moves and developments
  • 8.8.Sanofi S.A.
    • 8.8.1.Company overview
    • 8.8.2.Company snapshot
    • 8.8.3.Operating business segment
    • 8.8.4.Product portfolio
    • 8.8.5.Business performance
    • 8.8.6.Key strategic moves and developments
  • 8.9.Wockhadt Ltd.
    • 8.9.1.Company overview
    • 8.9.2.Company snapshot
    • 8.9.3.Operating business segment
    • 8.9.4.Product portfolio
    • 8.9.5.Business performance